SCHEMBL13675780

SCHEMBL13675780

CC(C)(C)c1ccc(/C=C/C(=O)Nc2cccc(Cl)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.72
MMP1 P03956 4/20 0.72
MMP2 P08253 4/20 0.72
MMP9 P14780 4/20 0.72
MAOA P21397 3/20 0.72
TRPV1 Q8NER1 10/20 0.71
EGFR P00533 1/20 0.71
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
NPC1 O15118 2/20 0.62
RAB9A P51151 2/20 0.62
MAPT P10636 4/20 0.61
MAPK1 P28482 3/20 0.61
KDM4E B2RXH2 1/20 0.61
LMNA P02545 1/20 0.61
POLB P06746 1/20 0.61
HPGD P15428 1/20 0.61
TSHR P16473 2/20 0.59
HDAC6 Q9UBN7 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3997459 0.86 MMP1 (0.75) MAOBMMP1MMP2MMP9MAOA
SCHEMBL3997455 0.86 MMP1 (0.75) MAOBMMP1MMP2MMP9MAOA
SCHEMBL13675776 0.86 MMP1 (0.74) MAOBMMP1MMP2MMP9MAOA
SCHEMBL13675636 0.85 TRPV1 (0.71) MAOBMMP1MMP2MMP9TRPV1
SCHEMBL13675774 0.84 TRPV1 (0.74) MMP1MMP2MMP9TRPV1EGFR
SCHEMBL4006429 0.84 TRPV1 (1.00) MAOBMMP1MMP2MMP9MAOA
SCHEMBL4006434 0.84 TRPV1 (1.00) MAOBMMP1MMP2MMP9MAOA
N-(3-Chlorophenyl)Cinnamamide SCHEMBL15176818 0.84 MAOB (1.00) MAOBMMP1MMP2MMP9MAOA
SCHEMBL22367627 0.83 MAOB (0.74) MAOBMMP1MMP2MMP9MAOA
SCHEMBL22367626 0.83 MAOB (0.74) MAOBMMP1MMP2MMP9MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 MAOB 1152/4885MMP1 1052/4885MMP2 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.